Relypsafounded In 2007 And Based In Santa Claracaliforniais A Clinical Stage Biopharmaceutical Company That Specializes In Non Absorbed Polymeric Drugs For Cardiovascular And Renal Diseasesacquired By Galenica In 2016Relypsa Became Part Of Vifor Pharmafocusing On Gastrointestinal Disordershepatologyand Hypolipidemic Agents The Company S Flagship Productveltassaa Patiromer Is An Fda Approved Potassium Binder Used To Treat Hyperkalemia In Patients With Chronic Kidney Diseaserelypsa Also Developed Rly5016A Polymer Aimed At Managing Electrolyte Imbalanceswith A Strong Patent Portfolio Of 51 Patentsrelypsa Leverages Its Polymer Science Expertise To Create Drugs That Act Locally In The Gastrointestinal Tractminimizing Systemic Side Effectsthe Company Continues To Operate Under The Vifor Pharma Namefocusing On Nephrology And Cardio Renal Therapies
